Results Set Stage for Phase 2 Trial of Investigational Vaccine Affitope PD01A, Affiris Says
Multiple administrations of Affitope PD01A, an investigational vaccine for Parkinson’s disease, elicit a safe and sustained immune response against alpha-synuclein — a protein involved in the development of Parkinson’s — in patients at the early stages of the disease, according to results from a Phase 1…